JP2005506346A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506346A5
JP2005506346A5 JP2003535724A JP2003535724A JP2005506346A5 JP 2005506346 A5 JP2005506346 A5 JP 2005506346A5 JP 2003535724 A JP2003535724 A JP 2003535724A JP 2003535724 A JP2003535724 A JP 2003535724A JP 2005506346 A5 JP2005506346 A5 JP 2005506346A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
phenyl
phenylalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003535724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506346A (ja
Filing date
Publication date
Priority claimed from US09/982,123 external-priority patent/US6531467B2/en
Priority claimed from US10/007,632 external-priority patent/US6610683B2/en
Application filed filed Critical
Publication of JP2005506346A publication Critical patent/JP2005506346A/ja
Publication of JP2005506346A5 publication Critical patent/JP2005506346A5/ja
Pending legal-status Critical Current

Links

JP2003535724A 2001-10-16 2002-10-16 インターロイキン−１β−変換酵素（ＩＣＥ）／ＣＥＤ−３ファミリーインヒビターを使用する感染症の治療 Pending JP2005506346A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/982,123 US6531467B2 (en) 1996-09-12 2001-10-16 Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US10/007,632 US6610683B2 (en) 1996-09-12 2001-11-13 Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
PCT/US2002/033157 WO2003032918A2 (en) 2001-10-16 2002-10-16 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors

Publications (2)

Publication Number Publication Date
JP2005506346A JP2005506346A (ja) 2005-03-03
JP2005506346A5 true JP2005506346A5 (enExample) 2006-01-05

Family

ID=26677222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003535724A Pending JP2005506346A (ja) 2001-10-16 2002-10-16 インターロイキン−１β−変換酵素（ＩＣＥ）／ＣＥＤ−３ファミリーインヒビターを使用する感染症の治療

Country Status (6)

Country Link
US (3) US6610683B2 (enExample)
EP (1) EP1443935A4 (enExample)
JP (1) JP2005506346A (enExample)
AU (1) AU2002357660A1 (enExample)
CA (1) CA2463729A1 (enExample)
WO (1) WO2003032918A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
EP2287326A1 (en) * 2003-08-08 2011-02-23 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
KR101361892B1 (ko) * 2003-10-08 2014-02-12 가부시키가이샤 자오 니콘 기판 반송 장치 및 기판 반송 방법, 노광 장치 및 노광 방법, 디바이스 제조 방법
ATE530165T1 (de) * 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
EP1737499A4 (en) * 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
CN102362867A (zh) 2004-05-15 2012-02-29 沃泰克斯药物股份有限公司 使用ice抑制剂治疗癫痫发作
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1778221A2 (en) 2004-05-27 2007-05-02 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
US7384558B2 (en) * 2004-07-26 2008-06-10 Baxter International Inc. Compositions capable of inhibiting reactive oxygen and carbonyl species
US20060073504A1 (en) * 2004-09-20 2006-04-06 The Regents Of The University Of California Treatment of pain by inhibition of caspase signaling
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
US8642596B2 (en) * 2004-12-06 2014-02-04 Siga Technologies, Inc. Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses
US8410149B2 (en) 2004-12-06 2013-04-02 Siga Technologies Inc. Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
US7994221B2 (en) 2004-12-06 2011-08-09 Siga Technologies, Inc. Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
WO2008045017A2 (en) * 2005-06-22 2008-04-17 Diamond Scott L Sars and ebola inhibitors and use thereof, and methods for their discovery
CN101034257B (zh) * 2007-04-06 2010-09-08 上海复旦天臣新技术有限公司 用于全息记录的感光薄膜及其制备方法
EP2635906A4 (en) 2010-11-05 2014-04-02 Univ Brandeis Ice inhibiting compounds and uses thereof
CN103196739A (zh) * 2013-04-10 2013-07-10 哈尔滨体育学院 一种优秀冰雪运动员肌细胞凋亡鉴定方法
CN107029221A (zh) * 2017-01-26 2017-08-11 上海交通大学 胱氨酸蛋白酶抑制剂在制备防治紫外光诱导的皮肤损伤药物、保健品及各种制剂中的应用
CA3239611A1 (en) * 2021-12-08 2023-06-15 Hui Xiong Compounds specific to granzyme b and uses thereof
EP4444301A4 (en) * 2021-12-08 2025-12-24 Cytosite Biopharma Inc PROMEDICAMENTS FOR SPECIFIC GRANZYME B COMPOUNDS AND ASSOCIATED USES
WO2024254479A2 (en) * 2023-06-07 2024-12-12 Cytosite Biopharma Inc. Prodrugs for compounds specific to granzyme b and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
WO1991015577A1 (en) 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE
EP0600880B1 (en) 1991-08-30 2004-01-07 Vertex Pharmaceuticals Incorporated Interleukin 1- beta protease and interleukin 1-beta protease inhibitors
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
US5514694A (en) * 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
US5504080A (en) 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
EP0706525A1 (en) 1993-06-30 1996-04-17 Novartis AG Antihypertensive tricyclic azepine derivatives useful as inhibitors of enkephalinase and ace
AU739321B2 (en) * 1996-09-12 2001-10-11 Idun Pharmaceuticals, Incorporated C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
ATE215953T1 (de) * 1996-09-12 2002-04-15 Idun Pharmaceuticals Inc Neue tricyclische verbindungen mit ice/ced-3 protease familie-hemmenden eigenschaften
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5968927A (en) * 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
FR2775594B1 (fr) * 1998-03-06 2002-12-27 Oreal Utilisation d'un compose inhibant l'activite d'un canal sodium ou d'un canal calcium dans une composition a usage topique

Similar Documents

Publication Publication Date Title
JP2005506346A5 (enExample)
US6669966B1 (en) Compositions for facilitating skin growth and methods and articles using same
ES2323395T3 (es) Procedimiento y composicion para el tratamiento de irritaciones e infecciones epidermicas.
AU1435901A (en) Compositions and methods for facilitating skin growth and managing skin conditions
JP2010505817A5 (enExample)
US3856805A (en) Silver zinc allantoin complex
CA2895249C (en) Topical oral composition for alleviating dry mouth symptoms and for treating mouth ulcers
US5028414A (en) Anaerobe-selective antibacterial compositions and methods
US4804530A (en) Anaerobe-selective antibacterial compositions and methods
US6251371B1 (en) Treatment of skin or mucosa inflammation by topical treatment with preparation containing dichlorobenzyl alcohol
Schwartz Cosmeceutical metals
JP2001089383A (ja) 口腔用及び眼科用組成物
US20060105057A1 (en) Compositions using tetrasilver tetroxide and methods for management of skin conditions using same
EP0105448B1 (en) The use of undecylenic acid for the manufacture of a composition for the treatment of herpes labialis
CN1303967C (zh) 以褪黑素作为活性成分供人类使用的牙膏或漱口水及动物饲料
JP5650642B2 (ja) メチオニンアナログおよびそれらを使用する方法
EP1663195B1 (en) Taurine bromamine for inhibiting pathogenic bacteria and fungi growth as well as in a microbicidal composition
EP0228137B1 (en) Anaerobe-selective antibacterial compositions
AU2002248004B2 (en) Agent for prophylaxis or treatment of inflammatory diseases in mucosa or oral cavity and the like
RU2026062C1 (ru) Паста для лечения пародонтита
CA2438164A1 (en) Use of preparations containing selenite or selenate
UA144398U (uk) Засіб у формі гелю для лікування гострого виразкового стоматиту
Madankar et al. Potassium Alum in Modern Aftershave: Multidimensional Mechanisms, Formulation Advances, and Dermatological Safety for Sustainable Skincare
RU2005122467A (ru) Способ химической стабилизации собилизированного ретиноида и водная композиция, полученная этим способом, содержащая по меньшей мере один ретиноид в виде соли
US9616003B2 (en) Antibacterial mouthwash which is nontoxic in cellular level